New FDA Guidance On PDURS Ushers In A New Era for Digital Innovation In Life Sciencesimage placeholder

New FDA Guidance On PDURS Ushers In A New Era for Digital Innovation In Life Sciences

This deep dive explores how the FDA’s draft PDURS guidance enables pharma companies to integrate digital solutions into their products, enhancing patient engagement and adherence. We cover the opportunities this brings for improving patient outcomes, how PDURS supports value-based healthcare, and the role of digital tools in creating a competitive edge in a crowded market.

by
Emilia Kruzel, PhD and Brooke Mastrorio
Be the first to know!
We'll send this deep dive to you as soon as it's published. Stay informed and subscribe.
Thank you! This deep dive is ready to download.
We'll send this deep dive to you as soon as it's published. Stay informed and subscribe.
Download PDF
Oops! Something went wrong while submitting the form.
Be the first to know!
We'll send this deep dive to you as soon as it's published. Stay informed and subscribe.
Thank you! This deep dive is ready to download.
Thank you! This deep dive is ready to watch.
Watch the recording
Oops! Something went wrong while submitting the form.
you may also like
Cover of the whitepaper titled 'A transformative approach to treating obesity: integrating digital health technology into healthcare strategies for life sciences and insurers,' displayed on a blue background.placeholder image
Transforming Obesity Treatment: Integrating Digital Health Technology into Payer and Life Sciences
placeholder image
How Gamification Takes Us One Step Closer to Value-Based Healthcare
Cover of Sidekick Health’s whitepaper on FDA’s 2023 draft guidance for Prescription Drug Use-Related Software (PDURS), exploring digital health innovation in Life Sciences across therapeutic areas such as oncology, cardiometabolic conditions, and dermatology.placeholder image
New FDA Guidance On PDURS Ushers In A New Era for Digital Innovation In Life Sciences